

DAY ONE – Thursday 13 May 2021

Cholangiocarcinoma (CCA), diagnosis and treatment updates

TIME	MIN	TOPIC	SPEAKER
SESSION 1: WELCOME AND OVERVIEWS			
09:30 – 09:45	15	Chairman's Welcome	Noel Corrigan <i>Chair – AMMF</i>
09:45 – 10:00	15	The work of AMMF – an overview	Helen Morement <i>CEO – AMMF</i>
10:00 – 10:20	20	CCA – an overview: what it is, what we currently know about it	Professor Shahid A Khan <i>Imperial College London</i>
10:20 – 10:40	20	The AMMF Data Project	Dr Sophie Jose <i>Health Data Insight</i>
10:40 – 10:50	10	Q&A – Re CCA overview and Coding and the Data Project	Moderator and Speakers Q's via the chat box
10:50 – 11:10	20	<i>Break</i>	<i>Poster Hall + Exhibitor Hall*</i>
SESSION 2: DIAGNOSTIC AND TREATMENT UPDATES			
11:10 – 11:30	20	Patient Viewpoint: My CCA Journey	Malcolm Robinson
11:30 – 11:50	20	Gall Bladder Cancer – an accessible biliary cancer	Professor Robert Goldin <i>Imperial College London</i>
11:50 – 12:10	20	Surgery for CCA – and why centres of expertise are necessary	Mr Hassan Malik <i>Aintree Hospital Liverpool</i>
12:10 – 12:30	20	Transplantation for CCA – an update	Professor Nigel Heaton <i>King's College Hospital, London</i>

TIME	MIN	TOPIC	SPEAKER
12:30 – 12:50	20	Q&A – Re pathology, surgery and transplantation	Moderator and Speakers Q's via the chat box
12:50 – 13:30	40	<i>Lunch Break</i>	<i>Poster Hall + Exhibitor Hall*</i>
13:30 – 13:50	20	Radiotherapy for CCA – where are we now?	Professor Maria Hawkins <i>University College London</i>
13:50 – 14:10	20	Building on our current treatments – is precision medicine the future for CCA?	Professor Juan Valle <i>University of Manchester/ The Christie</i>
14:10 – 14:30	20	Molecular profiling – its growing importance and how can UK and European CCA patients access it?	Professor John Bridgewater <i>University College London</i>
14:30 – 14:50	20	Q&A – Re treatments and molecular profiling	Moderator and Speakers Q's via the chat box
14:50 – 15:05	15	<i>Break</i>	<i>Poster Hall + Exhibitor Hall*</i>
15:05 – 15:35	30	Nutrition for the CCA patient Q&A via chat box	Glenda O'Connor <i>The Wellington Hospital, London</i> <i>Q&A Moderator:</i> Pam O'Donoghue
15:35 – 16:05	30	Ask the Expert – For patients and carers. Pre-submitted and chat box Q's answered by experts.	<i>Chair:</i> Dr Christopher Wadsworth <i>Expert Panel:</i> Professor Juan Valle Professor Maria Hawkins Mr Hassan Malik Professor Shahid A Khan
16:05 – 16:20	15	Day One Closing Remarks	Professor Shahid A Khan & Helen Morement

DAY TWO – Friday 14 May 2021

International aspects of cholangiocarcinoma (CCA) and scientific updates

TIME	MIN	TOPIC	SPEAKER
SESSION 3: INTRODUCTION TO DAY TWO			
09:30 – 09:40	10	Chairman's Welcome to Day Two	Noel Corrigan <i>Chair – AMMF</i>
09:40 – 10:00	20	Patient Viewpoint: Important lessons I've learned from CCA	Andrea Sheardown
SESSION 4: INTERNATIONAL ASPECTS OF CCA			
10:00 – 10:20	20	CCA in Southeast Asia	Professor Narong Khuntikeo <i>Khon Kaen University, Thailand</i>
10:20 – 10:40	20	CCA in China	Dr Shijie Cai <i>University of Oxford and West China Hospital, Sichuan University, China</i>
10:40 – 11:00	20	USP22 deubiquitination confers a more invasive phenotype to CCA	Dr Yu Tian <i>The Second Hospital of Dalian Medical University Dalian, Liaoning, PR China</i>
11:00 – 11:20	20	Break	Poster Hall + Exhibitor Hall*
11:20 – 11:40	20	ENS-CCA updates and the E-COST Project	Dr Vincenzo Cardinale <i>Sapienza University, Rome, Italy</i>
11:40 – 12:00	20	CCA in The Netherlands	Dr Heinz-Josef Klumpen <i>Amsterdam University Medical Center, University of Amsterdam, The Netherlands</i>
12:00 – 12:20	20	Q&A – Re international aspects	Moderator and Speakers Q's via the chat box
SESSION 5: SCIENTIFIC UPDATES – AMMF-FUNDED RESEARCH			
12:20 – 12:40	20	Identifying tumour suppressors that interact with oncogenic Kras in intrahepatic CCA	Mollie Wilson <i>University of Edinburgh</i>

TIME	MIN	TOPIC	SPEAKER
12:40 – 13:00	20	Virus-driven intrahepatic CCA	Dr Stephen Griffin <i>University of Leeds</i>
13:00 – 13:20	20	New epigenetic therapies for experimental CCA	Professor Matías Avila <i>CIMA University of Navarra, Spain</i>
13:20 – 13:40	20	Q&A – Re first three AMMF-funded scientific presentations	<i>Chair:</i> Dr Christopher Wadsworth <i>Panel:</i> Speakers Q's via chat box
13:40 – 14:10	30	Lunch Break	Poster Hall + Exhibitor Hall*
14:10 – 14:30	20	The therapeutic benefit of targeting Wnt receptors in metastatic CCA	Dr Toby Phesse <i>Cardiff University</i>
14:30 – 14:50	20	Identification of actionable targets in peri-hilar CCA using whole exome sequencing	Mr Marc Quinn <i>University of Liverpool</i>
14:50 – 15:10	20	TWEAK/Fn14 signalling promotes CCA niche formation and progression	Dr Ben Dwyer <i>Edinburgh / Curtin University Perth, Western Australia</i>
15:10 – 15:30	20	Q&A – Re final three AMMF-funded scientific presentations	<i>Chair:</i> Dr Christopher Wadsworth <i>Panel:</i> Speakers Q's via chat box
15:30 – 15:50	20	Break	Poster Hall + Exhibitor Hall*
SESSION 6: SCIENTIFIC UPDATES AND DEVELOPMENTS			
15:50 – 16:20	30	Optimizing chemotherapy activity with the use of novel biomarkers and Q&A	Dr Chiara Braconi <i>University of Glasgow</i>
16:20 – 17:00	40	Experimental Models of Liver Cancer and Q&A	Dr Luke Boulter and Dr Chiara Braconi
17:00 – 17:10	10	End of Conference Closing Remarks	TBC

*Please note: Poster + Exhibitor Halls are intended for HCPs only.

Times shown are GMT. For CET +1 hour.

Programme correct as at 10.05.2021